Figure 3.

Increases in ACR20, ACR50, and ACR70 scores in patients with rheumatoid arthritis who failed previous disease-modifying antirheumatic drug therapy and were given one of four dosages of adalimumab or placebo. Adapted with permission from the BMJ Publishing Group [32].

Schwartzman et al. Arthritis Res Ther 2004 6(Suppl 2):S3-S11   doi:10.1186/ar1013